A development of Ontuxizumab, initially known as MORAb-004, illustrates a important endeavor in immunotherapy. Scientists at its developers started studies on a modified monoclonal immunoglobulin targeting CD3, focused https://tomassjyr507263.blog5.net/92086302/ontuxizumab-morab-004-a-deep-dive-into-its-development